Home

  • Dante Genomics’ sequencing hub in Dubai receives ISO 15189 Medical Laboratory accreditation to bring clinical whole genome sequencing to the next billion patients

    Dante Genomics’ sequencing hub in Dubai receives ISO 15189 Medical Laboratory accreditation to bring clinical whole genome sequencing to the next billion patients

    NEW YORK, January 25, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, announced today that their laboratory in Dubai, which serves as a global hub for the Eastern Hemisphere, has received Medical Laboratory accreditation ISO 15189 to bring clinical whole genome sequencing to hospitals and physicians in the Middle East, Asia and Africa.

    The ISO 15189 certifies the quality management system of medical laboratories and is often a requirement to provide clinical sequencing tests or sequencing services to the biopharma industry. 

    “Dante is a global company now with more than six years of experience delivering whole genome sequencing around the world,” 

    said Andrea Riposati, co-founder and CEO of Dante Genomics. 

    “We have invested in the UAE to expand our reach to geographical areas and deliver customized whole genome sequencing solutions to the next billion people.”

    Dante Genomics received the ISO 13485 for medical devices for its Extensa interpretation software in 2020, renewing it in 2021 and again in 2022. The new ISO 15189 is a testament to the Company’s continued investment in quality.

    Dante Genomics developed a hybrid approach of local sequencing laboratories in strategic locations with the addition of partnership labs in several other countries to deliver whole genome sequencing globally at scale in more than 97 countries. 

    The Company’s analysis and interpretation leverages the proprietary Dante Platform to deliver clinically relevant reports with actionable insights, so doctors can help their patients make informed healthcare decisions that impact their lives.

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics to present at the 41st Annual J.P. Morgan Healthcare Conference

    Dante Genomics to present at the 41st Annual J.P. Morgan Healthcare Conference

    NEW YORK, January 3, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco next week. Andrea Riposati, CEO of Dante Genomics, will present on Tuesday, January 10, 2023 at 4:30 PM Pacific Time at The Westin St. Francis. 

    “We are thrilled to be presenting at the J.P. Morgan Healthcare Conference this year,” said Andrea Riposati, co-founder and CEO of Dante Genomics. “The future of healthcare needs whole genome sequencing, and I look forward to attending the conference and sharing how Dante Genomics is impacting lives around the world with whole genome sequencing.” 

    The Annual J.P. Morgan Healthcare Conference is by invitation only, and it is the premier financial event of the year in healthcare. The conference is one of the largest and most informative healthcare investment symposiums in the industry connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. 

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io

    Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io

    – Dante Genomics uses the 1health.io platform to accelerate their go to market strategy and expand availability in all 50 states using the 1health online prescription services –

    NEW YORK, December 7, 2022 – 1health.io Inc. (“1health”), an industry-leading software company that empowers laboratories to launch new test products quickly into both clinical and online markets, partners with Dante Genomics, a global leader in genomics and precision medicine, to help launch their whole genome sequencing test to their customers in the United States with online prescription services. 

    Dante Genomics is a global genomic information company that delivers clear, understandable medical reports to its customers based on whole genome sequencing. Once a person has sequenced their whole genome through Dante, they will have access to more than 90 clinical and wellness reports. These reports are generated at the click of a button within minutes with no need to re-test. Genetic counseling will also be made available to these customers. The idea is to integrate fast, accurate genomic information into healthcare to deliver more personalized medicine when you need it. 

    Dante Genomics is streamlining complex prescription workflows by integrating with the 1health platform which provides access to a network of independent physicians for users to obtain a prescription to order their test by answering a few questions at order entry and upload clinical records if needed to receive approval and obtain a prescription. Now, using 1health’s online portal, consumers located anywhere across the United States can get a prescription upon approval to order their whole genome sequencing test, which provides them with the health data they need to understand their health and make informed and proactive decisions about their health whether preventive or exercising symptoms.

    “Personalized medicine needs personalized data, and the whole genome is the most personalized data available to an individual to inform better healthcare decisions,”

    said Andrea Riposati, CEO of Dante Genomics.

    “We like to say, ‘sequence your data once, query it for a lifetime.’ Now, in collaboration with 1health, we will be able to bring doctor-ordered whole genome sequencing to our customers in the U.S. with understandable, clinical reports available at your fingertips within minutes.” 

    “1health mission is to make advanced diagnostic testing more accessible and affordable in healthcare,” states Mehdi Maghsoodnia, Chief Executive Officer of 1health. “Having Dante Genomics on the 1health platform provides clinicians with some of the most advanced genomic testing to enable personalized precision care for their patients.”

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    About 1health.io

    1health is driving healthcare innovation by empowering our laboratory partners to make modern diagnostic testing more accessible, affordable and simple in the healthcare industry. 1health provides laboratories with a modern, secure and easy to use software platform that makes it easy to launch new test products, onboard new clinical customers and compete in the growing at home and online commerce markets.  The result is stronger, more-trusted relationships between laboratories and their customers, better healthcare outcomes for consumers, and ultimately more lives saved.

    For further information:

    Dante Genomics 
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

    1health Media 

    Yasmin Hariri

    Head of Marketing

    yhariri@1health.io

    www.1health.io

  • Al Farabi Medical Laboratories and Dante Genomics announce global partnership for the delivery of Next Generation Sequencing Genomic Testing in the Kingdom of Saudi Arabia

    Al Farabi Medical Laboratories and Dante Genomics announce global partnership for the delivery of Next Generation Sequencing Genomic Testing in the Kingdom of Saudi Arabia

    NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Al Farabi Medical Laboratories, the leading medical laboratories in the Kingdom of Saudi Arabia with more than 50 labs covering all regions of the Kingdom, and Dante Genomics, a global leader in genomics and precision medicine, are pleased to announce a commercial partnership to provide patients with a wide range of clinical genomic tests, including Whole Genome Sequencing and Whole Exome Sequencing with interpretation, as well as Non-Invasive prenatal Testing (NIPT) in Saudi Arabia.

    “We are delighted to offer advanced genomic testing services in partnership with the Al Farabi Medical Labs in the Kingdom of Saudi Arabia,”

    said Andrea Riposati, Dante Genomics CEO and Co-founder.

    “We look forward to supporting the growth of Al Farabi Medical Labs and its cutting-edge vision. Together, we aim to enable whole genome sequencing driven healthcare for individuals.”

    Dr. Mohamed Marie, Al Farabi Founder and General Manager, said: 

     “We are honored to leverage Dante Genomics technology and expertise in the Kingdom of Saudi Arabia. Al Farabi is a leading medical lab with more than 50 branches across the Kingdom. Dante Genomics will be our partner in genetic testing and other genomic solutions. We aim to offer the highest quality services to our patients, now in genomics, as we have done in all areas in healthcare.”

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    About Al Farabi Medical Labs

    Al Farabi Medical Labs has pursued since its inception and still the policy of attracting and localizing the new and modern in various diagnostic techniques to work on difficult equations in the medical field in terms of quality of performance, speed of results and fair price for the service provided. Al Farabi Medical Labs has followed a strict policy to adhere to international and local standards and requirement for laboratory quality and occupational safety. This has resulted in achieving national and international accreditations, CBAHI and JCI, respectively.

    For further information:

    Marketing and Public relations Department
    Dr. Kareem Shaheen
    Marketing manager
    k.shaheen@alfarabilabs.com

    Dr. Murad Al Mubaraki
    Medical Director
    mamubaraki@alfarabilabs.com

    Dante Genomics
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com 

  • Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, announced that the Company will be participating in The Canaccord Genuity MedTech Diagnostics and Digital Health and Services Forum. Andrea Riposati, CEO of Dante Genomics, will present at the conference on Thursday, November 17, 2022 at 9:30 AM Eastern Time.

    A live and archived webcast of the presentation will be available at the conference link here.

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    http://www.dantegenomics.com

  • Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe

    Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe

    L’AQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) — Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.

    WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, services and resources. Longenesis will enrich its digital engagement platform by offering its network of participants discounted Dante offerings, including at-home, blood collection kits for WGS without the use of a needle and additional women’s health reports without the need to re-test. This collaboration will encourage more people to pursue genomic solutions to help make personalised medicine more mainstream across Europe.

    The Longenesis platform offers a digital, dynamic, secure engagement tool that empowers the public to explore and start using Dante’s novel genomic solutions. These digital tools will ensure legal and ethical compliances built into the Longenesis platform and offer streamlined consent for nearly 20,000 women globally.

    “Our new partnership with Dante Genomics will make it easier for women to access exciting new DNA testing opportunities that will provide greater health insights. Everyone deserves to have an individualised understanding of their health that DNA testing affords. We are excited to work with Dante Genomics to expand our European reach and positively impact more patients’ lives,”

    said Paolo Malerba, VP of Partnerships and Strategy at Longenesis.

    “Personalised medicine needs personalised data, and it is through collaborations like these that will allow us to offer more people in more regions of the world with genomic solutions,” said Andrea Riposati, CEO of Dante Genomics. “We are excited to partner with Longensis to increase access to these invaluable genomic solutions that can improve women’s health and ultimately save lives.”

    About Longenesis

    Longenesis is a SaaS company that is unlocking a healthier future for humans. Supported by Insilico Medicine and other technology leaders, Longenesis has built an end-to-end, intuitive toolkit for data discovery and patient-centric engagement that prioritizes privacy and ethics. Our flagship products, Curator and Engage, are highly secure and designed for patients to remain in control of their personal data while also empowering them to share their information with doctors and researchers worldwide. Through these products, we unlock the hidden value of data, accelerate novel drug and treatment discovery, and ensure better and more proactive patient engagement. Our mission is to help modernize the approach to human health. At Longenesis, we firmly believe the future medical system will be collaborative. We build a technological bridge between healthcare institutions, pharma companies, research institutions and patients. We are proud to partner with leading educational and research institutions, global life sciences companies, healthcare stakeholders, and patient advocacy groups in service of this mission. Learn more at www.longenesis.com.

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    media@longenesis.com
    ir@dantelabs.com

  • Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.

    Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.

    NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity. Genomic Biopharma Inc. will present two abstracts on two drug programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting, the first of which is a top scoring abstract at the meeting titled:

    • Abstract Title: A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA vaccine 
      Presentation Date/Time: Wednesday, October 26, 2022, 3:00 PM – 4:45 PM Pacific Time
    • Abstract Title: Novel siRNA-based therapeutic approach for Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) 
      Presentation Date/Time: Thursday, October 27, 2022, 3:00 PM – 4:45 PM Pacific Time

    “Dante Genomics has delivered genomic insights and diagnoses to thousands of individuals, ending many years-long diagnostic odysseys,” said Mattia Capulli, Chief Scientific Officer of Dante Genomics. “Through the creation of Genomic Biopharma Inc. we will realize our vision to support the discovery and development of personalized medicine, so that no one is diagnosed with a disease for which there is no treatment.”

    Genomic Biopharma Inc. was created as a fully integrated drug discovery and development company, with a pipeline of drug programs for treatments and therapies focused on infectious and rare diseases. The Company develops its pipeline based on findings from Dante Genomics’ proprietary database of whole genomes. Genomic Biopharma’s core technology, the GBI AI, uses predictive algorithms and genomic data mining to support the identification of novel RNA-based therapeutics.

    “Personalized medicine requires an integrated approach from data to clinical trials,” said Andrea Riposati, CEO of Dante Genomics. “We created Genomic Biopharma as a separate, independent company, to achieve the vision of personalized medicine and unlock the new era of genomic data based therapeutics.”

    Dante Genomics provided initial funding and resources to Genomic Biopharma Inc. to kick off the new entity’s endeavors and programs. The two companies are now independent.

    About Genomic Biopharma Inc.

    Genomic Biopharma Inc. is a drug discovery and development company building a pipeline of drug programs focused on bringing to market treatments and therapies for infectious and rare diseases. The Company develops its pipeline based on findings from Dante Genomics’ proprietary database of whole genomes. Genomic Biopharma’s core technology, the GBI AI, uses predictive algorithms and genomic data mining to support the identification of novel RNA-based therapeutics.

    Contact:

    info@genomicbiopharma.com
    www.genomicbiopharma.com

  • Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit

    Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit

    NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

    “Whole genome sequencing could be a game changer for 100x faster diagnosis for rare diseases, and we look forward to exploring a living lab opportunity in Ireland with Dante Genomics,” said Professor Martin Curley, United Nations General Assembly Symposium Chair.

    The United Nations Science Summit discussed global standards to leapfrog digital health adoption by countries and healthcare systems across five continents, highlighting the need for private organizations to drive change in public healthcare systems.

    “Personalized medicine needs personalized data, and the whole genome is the most personalized data available to an individual to inform better healthcare decisions,”

    said Andrea Riposati, CEO of Dante Genomics.

    “We are thrilled to launch Digital Health Population Genomics programs in Europe, further implementing Dante’s model to sequence your whole genome once and query it for a lifetime. Living labs allow for prompt impact on a country’s healthcare system, enabling benefits for all starting with patients.”

    The first two genomic programs will launch in October 2022 with the first testing individuals for rare diseases and the second focused on prevention for healthy individuals. The data coming out of these programs will demonstrate the potential for new initiatives, offering European countries the ability to leverage Dante Genomics’ advanced platform to offer end-to-end solutions without the data and samples needing to leave the country.

    About Dante Genomics

    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contacts:

    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

    TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine.

    “The simple act of providing a whole genome sequence is likely the single most important piece of healthcare for a patient with a rare disease, and no child or family should have to needlessly suffer because they can’t afford it,” said Joshua Resnikoff, CEO and Cofounder of TMA Precision Health. “Our mission is to bring this service to those that need it most. We are thrilled to partner with Dante Genomics to bring the highest quality genomic sequencing and interpretation services to our patients around the globe.”

    Dante Genomics will provide 30X whole genome sequencing, clinical interpretation and personalized genomic reports to TMA’s patient network of more than 3.5 million people living with rare diseases for the purposes of diagnosis.

    “There are so many people, especially children, suffering from undiagnosed rare diseases around the world, and it is this unmet need that we are working to serve every day,” said Andrea Riposati, CEO and co-founder of Dante Genomics. “We must work to end any diagnostic odyssey for these patients and reduce the time to diagnosis from years to days. Children with a rare disease, in any country, deserve the best clinical care, and TMA Precision Health is at the frontier to bring genomic driven care to the countries with the highest unmet need.”

    Dante Genomics will utilize the genomic data related to this partnership to advance internal research related to novel target identification and drug development with the ultimate goal to go beyond diagnosis to treatment of rare disease.

    TMA will incorporate the data from this partnership to continue growing the largest rare disease database in the world, with a focus on developing precision medicine solutions for rare patients everywhere.

    About TMA Precision Health
    TMA Precision Health is on a mission to provide personalized care and health equity for rare disease patients around the world. Our unique access to more than 3.5 million rare disease patients powers our ability to build on-demand comprehensive datasets of paired de-identified medical records and whole genomic sequencing and identify rare patients for clinical trials, giving our pharma partners a competitive edge when researching new insights and developing new treatments for this area of critically unmet need. For more information, please visit tmaprecisionhealth.com and follow us on LinkedIn.

    About Dante Genomics
    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contacts:
    Joshua Resnikoff
    CEO of TMA Precision Health
    info@tmaprecisionhealth.com
    www.tmaprecisionhealth.com

    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com

  • Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

    Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

    NEW YORK, September 1, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, announced today that the Company has begun using needleless, at-home blood collection kits for its premium clinical whole genome sequencing test, thus bringing the high quality of concierge clinics to at home testing.

    Dante Genomics is utilizing these at-home blood collection kits for its whole genome sequencing on the www.dantelabs.com website, making it easier than ever and virtually painless for patients to collect their blood sample on their own without having to travel to a hospital or have direct interaction with a mobile phlebotomist. 

    “This groundbreaking innovation comes from our relentless focus on providing universal access to the highest quality genomics technologies,” said Andrea Riposati, CEO of Dante Genomics. “Anyone, anywhere in the world, deserves to receive the most advanced genomic care. Anyone. Anywhere.”

    The collection of blood samples for the use of genomics sequencing has key advantages over the collection of saliva:

    • Saliva-derived DNA contains significantly less DNA than blood-derived DNA.
    • There is far less risk of DNA contamination due to user error.
    • Blood samples have a higher percentage of passing Quality Control standards, avoiding the need for the customer to supply an additional sample to be re-tested.  
    • As a result, blood collection lowers turnaround times significantly for the customer. 

    With this innovation, individuals anywhere in the world get access to the highest quality of genomic testing and now also the best options for sample collection.

    Dante has deployed two products for blood collection: 

    • For the US market, an  FDA registered device that collects whole liquid blood samples that are ready to be used for genomic DNA isolation and sequencing. Users can successfully collect blood samples at home without direct interaction at a lab or with a mobile phlebotomist. 
    • For the European market, a CE-IVD marked device delivers whole dried blood samples from the patient to the lab. Subjects can successfully collect volumetrically precise samples. 

    For our DNA wellness programs and other specific applications, Dante will continue to offer its saliva collection kit as an option.

    About Dante Genomics
    Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:
    Laura D’Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantegenomics.com